Spyre Therapeutics, Inc.

XNASHealth care

Last traded price · USD

$99.04

+0.00%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 16:00 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $99.04
Volume: 2
Day's high: —
Day's low: —

In brief

Spyre Therapeutics, Inc. is a health care company listed on Nasdaq, valued at about $9.26B.
Its shares closed at $99.04 on 4 Nov 2026, up 331.0% over the past year.
From India you can buy SYRE in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Spyre Therapeutics, Inc. (SYRE) shares from India?

Yes. Indian residents can invest in the US stock market under the Reserve Bank of India's Liberalised Remittance Scheme (LRS), which lets a resident individual remit up to USD 250,000 per financial year, across all permitted purposes combined. US-listed stocks and ETFs are a permitted investment under the LRS. You are solely responsible for ensuring your remittances comply with the LRS annual limit, the applicable Tax Collected at Source (TCS) rules, and all reporting requirements, including Schedule FA in your income-tax return.

Do I need the price of a whole SYRE share to invest?

Yes. You can buy fractional shares, which lets you invest a fixed rupee/dollar amount even in high-priced stocks. For example, if one share trades at USD 1,000 and you invest USD 100, you receive 0.1 of a share.

How much can I invest in US stocks in a year?

Under the LRS, an Indian resident can remit up to USD 250,000 per financial year (April to March) across all permitted purposes combined, from their own funds. This is a per-individual limit set by the RBI.

Can I trade SYRE options or futures?

No. Under RBI / FEMA rules, the LRS does not permit margin trading or speculative instruments such as futures, options, or other derivatives. Your US account is a cash account, not a derivatives and margin account.

Insights

Quotes run fifteen minutes behind.

Ahead of SPY and its sector fund XLV over 1 year
1 month: +23.6% (SPY −1.6%, XLV +13.5%). 3 months: −5.1% (SPY −0.4%, XLV +15.5%). 1 year: +331.0% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: SYRE, SPY and XLV · as of 4 Nov 2026
10.1% below its 52-week high
Closed at $99.04 on 4 Nov 2026: 10.1% below the 52-week high of $110.18 (19 Aug 2026) and 368.4% above the low of $21.15 (7 Nov 2025).
Daily price bars, split-adjusted · as of 4 Nov 2026
7.3 days to cover short interest
12.5M shares were sold short at the 15 Oct 2026 settlement, 12.3% of the 101.9M shares outstanding; covering them would take 7.3 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Above its 50- and 200-day averages
The 4 Nov 2026 close of $99.04 was 10.6% above its 50-day average ($89.52) and 33.5% above its 200-day average ($74.19). It has closed above the 200-day for 271 sessions, since 8 Oct 2025. The 50-day average crossed above the 200-day on 22 Oct 2025, 260 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month+23.6%

6 months+35.7%

1 year+331.0%

5 years—

Newswire

About

Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.

Website

Notable moves

April 13, 2026
+23.36%
October 9, 2025
+19.74%
June 17, 2024
−19.30%

Spyre Therapeutics, Inc.

XNASHealth care

Last traded price · USD

$99.04

+0.00%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 16:00 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $99.04
Volume: 2
Day's high: —
Day's low: —

In brief

Spyre Therapeutics, Inc. is a health care company listed on Nasdaq, valued at about $9.26B.
Its shares closed at $99.04 on 4 Nov 2026, up 331.0% over the past year.
From India you can buy SYRE in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Spyre Therapeutics, Inc. (SYRE) shares from India?

Do I need the price of a whole SYRE share to invest?

How much can I invest in US stocks in a year?

Can I trade SYRE options or futures?

Insights

Quotes run fifteen minutes behind.

Ahead of SPY and its sector fund XLV over 1 year
1 month: +23.6% (SPY −1.6%, XLV +13.5%). 3 months: −5.1% (SPY −0.4%, XLV +15.5%). 1 year: +331.0% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: SYRE, SPY and XLV · as of 4 Nov 2026
10.1% below its 52-week high
Closed at $99.04 on 4 Nov 2026: 10.1% below the 52-week high of $110.18 (19 Aug 2026) and 368.4% above the low of $21.15 (7 Nov 2025).
Daily price bars, split-adjusted · as of 4 Nov 2026
7.3 days to cover short interest
12.5M shares were sold short at the 15 Oct 2026 settlement, 12.3% of the 101.9M shares outstanding; covering them would take 7.3 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Above its 50- and 200-day averages
The 4 Nov 2026 close of $99.04 was 10.6% above its 50-day average ($89.52) and 33.5% above its 200-day average ($74.19). It has closed above the 200-day for 271 sessions, since 8 Oct 2025. The 50-day average crossed above the 200-day on 22 Oct 2025, 260 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month+23.6%

6 months+35.7%

1 year+331.0%

5 years—

Newswire

About

Website

Notable moves

April 13, 2026
+23.36%
October 9, 2025
+19.74%
June 17, 2024
−19.30%

Spyre Therapeutics, Inc.

Spyre Therapeutics, Inc. in brief

Ahead of SPY and its sector fund XLV over 1 year

10.1% below its 52-week high

7.3 days to cover short interest

Above its 50- and 200-day averages

Spyre Therapeutics, Inc.

Spyre Therapeutics, Inc. in brief

Ahead of SPY and its sector fund XLV over 1 year

10.1% below its 52-week high

7.3 days to cover short interest

Above its 50- and 200-day averages